A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital

Sadanori Abe, Masao Kojima, Hikaru Tamura, Hiroaki Kurihara, Minoru Kitago, Tosihiro Kobayashi, Tetsuya Nakamura, Tomonobu Ogihara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A total of 40 patients with advanced and recurrent gastric cancer in our hospital were treated with TS-1 alone, and the efficacy of treatment, survival time, and adverse effects were examined. TS-1 was administered with the usual dosage and dose regimen. Response to treatment included a complete response (CR) in 3 cases, partial response (PR) in 8 cases, no change (NC) in 10 cases, and progressive disease (PD) in 7 cases. The response rate was 39.3%, and among the 28 patients with evaluable lesions TS-1 produced a high response rate of 56.3% in 16 patients who had undergone prior therapy. The median survival time (MST) was 478 days in the 28 patients with evaluable lesions, excluding patients with peritoneal dissemination, and 283 days in the 12 patients with peritoneal dissemination. The outcome was markedly poorer in the patients with peritoneal dissemination than in the patients with evaluable lesions. The incidence of grade 3 or higher adverse effects was 20%, including two cases in which decreased dihydropyrimidine dehydrogenase (DPD) activity was suspected, and one case in which decreased dihydropyrimidinase (DHP) was suspected. Although the effect of TS-1 alone on gastric cancer is significantly superior to that of any conventional cancer drugs, the results of this study suggest that the antitumor effect varies with the site of the target lesions and according to whether the lesion is a remnant or recurrence.

Original languageEnglish
Pages (from-to)963-970
Number of pages8
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number7
Publication statusPublished - 2003 Jul
Externally publishedYes

Fingerprint

Stomach Neoplasms
dihydropyrimidinase
Dihydrouracil Dehydrogenase (NADP)
Survival
titanium silicide
Recurrence
Incidence
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Abe, S., Kojima, M., Tamura, H., Kurihara, H., Kitago, M., Kobayashi, T., ... Ogihara, T. (2003). A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital. Gan to kagaku ryoho. Cancer & chemotherapy, 30(7), 963-970.

A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital. / Abe, Sadanori; Kojima, Masao; Tamura, Hikaru; Kurihara, Hiroaki; Kitago, Minoru; Kobayashi, Tosihiro; Nakamura, Tetsuya; Ogihara, Tomonobu.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 30, No. 7, 07.2003, p. 963-970.

Research output: Contribution to journalArticle

Abe, S, Kojima, M, Tamura, H, Kurihara, H, Kitago, M, Kobayashi, T, Nakamura, T & Ogihara, T 2003, 'A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 30, no. 7, pp. 963-970.
Abe, Sadanori ; Kojima, Masao ; Tamura, Hikaru ; Kurihara, Hiroaki ; Kitago, Minoru ; Kobayashi, Tosihiro ; Nakamura, Tetsuya ; Ogihara, Tomonobu. / A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2003 ; Vol. 30, No. 7. pp. 963-970.
@article{bfe0b3f31feb4673af5c312561929a87,
title = "A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital",
abstract = "A total of 40 patients with advanced and recurrent gastric cancer in our hospital were treated with TS-1 alone, and the efficacy of treatment, survival time, and adverse effects were examined. TS-1 was administered with the usual dosage and dose regimen. Response to treatment included a complete response (CR) in 3 cases, partial response (PR) in 8 cases, no change (NC) in 10 cases, and progressive disease (PD) in 7 cases. The response rate was 39.3{\%}, and among the 28 patients with evaluable lesions TS-1 produced a high response rate of 56.3{\%} in 16 patients who had undergone prior therapy. The median survival time (MST) was 478 days in the 28 patients with evaluable lesions, excluding patients with peritoneal dissemination, and 283 days in the 12 patients with peritoneal dissemination. The outcome was markedly poorer in the patients with peritoneal dissemination than in the patients with evaluable lesions. The incidence of grade 3 or higher adverse effects was 20{\%}, including two cases in which decreased dihydropyrimidine dehydrogenase (DPD) activity was suspected, and one case in which decreased dihydropyrimidinase (DHP) was suspected. Although the effect of TS-1 alone on gastric cancer is significantly superior to that of any conventional cancer drugs, the results of this study suggest that the antitumor effect varies with the site of the target lesions and according to whether the lesion is a remnant or recurrence.",
author = "Sadanori Abe and Masao Kojima and Hikaru Tamura and Hiroaki Kurihara and Minoru Kitago and Tosihiro Kobayashi and Tetsuya Nakamura and Tomonobu Ogihara",
year = "2003",
month = "7",
language = "English",
volume = "30",
pages = "963--970",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital

AU - Abe, Sadanori

AU - Kojima, Masao

AU - Tamura, Hikaru

AU - Kurihara, Hiroaki

AU - Kitago, Minoru

AU - Kobayashi, Tosihiro

AU - Nakamura, Tetsuya

AU - Ogihara, Tomonobu

PY - 2003/7

Y1 - 2003/7

N2 - A total of 40 patients with advanced and recurrent gastric cancer in our hospital were treated with TS-1 alone, and the efficacy of treatment, survival time, and adverse effects were examined. TS-1 was administered with the usual dosage and dose regimen. Response to treatment included a complete response (CR) in 3 cases, partial response (PR) in 8 cases, no change (NC) in 10 cases, and progressive disease (PD) in 7 cases. The response rate was 39.3%, and among the 28 patients with evaluable lesions TS-1 produced a high response rate of 56.3% in 16 patients who had undergone prior therapy. The median survival time (MST) was 478 days in the 28 patients with evaluable lesions, excluding patients with peritoneal dissemination, and 283 days in the 12 patients with peritoneal dissemination. The outcome was markedly poorer in the patients with peritoneal dissemination than in the patients with evaluable lesions. The incidence of grade 3 or higher adverse effects was 20%, including two cases in which decreased dihydropyrimidine dehydrogenase (DPD) activity was suspected, and one case in which decreased dihydropyrimidinase (DHP) was suspected. Although the effect of TS-1 alone on gastric cancer is significantly superior to that of any conventional cancer drugs, the results of this study suggest that the antitumor effect varies with the site of the target lesions and according to whether the lesion is a remnant or recurrence.

AB - A total of 40 patients with advanced and recurrent gastric cancer in our hospital were treated with TS-1 alone, and the efficacy of treatment, survival time, and adverse effects were examined. TS-1 was administered with the usual dosage and dose regimen. Response to treatment included a complete response (CR) in 3 cases, partial response (PR) in 8 cases, no change (NC) in 10 cases, and progressive disease (PD) in 7 cases. The response rate was 39.3%, and among the 28 patients with evaluable lesions TS-1 produced a high response rate of 56.3% in 16 patients who had undergone prior therapy. The median survival time (MST) was 478 days in the 28 patients with evaluable lesions, excluding patients with peritoneal dissemination, and 283 days in the 12 patients with peritoneal dissemination. The outcome was markedly poorer in the patients with peritoneal dissemination than in the patients with evaluable lesions. The incidence of grade 3 or higher adverse effects was 20%, including two cases in which decreased dihydropyrimidine dehydrogenase (DPD) activity was suspected, and one case in which decreased dihydropyrimidinase (DHP) was suspected. Although the effect of TS-1 alone on gastric cancer is significantly superior to that of any conventional cancer drugs, the results of this study suggest that the antitumor effect varies with the site of the target lesions and according to whether the lesion is a remnant or recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0042244481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042244481&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 963

EP - 970

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -